Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study To Evaluate The Efficacy, Safety, Tolerability and PK of MN-001 (Tipelukast) on HDL Function and Serum Triglyceride Levels in NASH and Non-Alcoholic Fatty Liver Disease (NAFLD) Subjects With Hypertriglyceridemia

NCT02681055 is registered in ClinicalTrials.gov with MediciNova as lead sponsor.

NCT NCT02681055
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02681055 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study To Evaluate The Efficacy, Safety, Tolerability and PK of MN-001 (Tipelukast) on HDL Function and Serum Triglyceride Levels in NASH and Non-Alcoholic Fatty Liver Disease (NAFLD) Subjects With Hypertriglyceridemia
Lead sponsor
MediciNova
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2016
Completion date
October 1, 2019
Enrollment
19 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hypercholesterolemia, hypertriglyceridemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis